Indi Molecular Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 9
Employees
  • Latest Deal Type
  • Series B
  • (In Progress)
  • Latest Deal Amount
  • $35M
Latest Deal Amount
  • Investors
  • 8

Indi Molecular General Information

Description

Developer of a fully synthetic class of therapeutic and molecular diagnostic agents designed to replace traditional antibodies. The company's protein catalyzed capture (PCC) agents can be deployed as both a precision-targeted therapeutic as well as an in vivo PET imaging agent, this dual role is accomplished by a shared chelation chemistry platform, enabling healthcare professionals to use application-specific therapeutic or PET imaging radionuclides to retain the specific pathology targeted PCC agent.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Primary Office
  • 6160 Bristol Parkway
  • Suite 200
  • Culver City, CA 90230
  • United States
+1 (310) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Indi Molecular Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) $35M 0000 In Progress
3. Later Stage VC 24-Jul-2020 0000 Completed Pre-Clinical Trials
2. Early Stage VC 31-May-2017 $11.5M $14M 000.00 Completed Pre-Clinical Trials
1. Seed Round 10-Dec-2013 $2.5M $2.5M 00.00 Completed Startup
To view Indi Molecular’s complete valuation and funding history, request access »

Indi Molecular Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 0,000,000 00.000000 00 00 00 00 00 00.000
To view Indi Molecular’s complete cap table history, request access »

Indi Molecular Executive Team (7)

Name Title Board Seat Contact Info
Heather Agnew Ph.D Vice President, Research and Development Operations
Michael Phelps Ph.D Advisor
Albert Luderer Ph.D Co-Founder, Chief Executive Officer & Board Member
James Heath Ph.D Co-Founder & Board Member
Leroy Hood Ph.D Co-Founder & Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

Indi Molecular Board Members (10)

Name Representing Role Since
Albert Luderer Ph.D Self Co-Founder, Chief Executive Officer & Board Member 000 0000
Cheryl Zimberlin Ph.D M Ventures Board Member 000 0000
Douglas Fisher MD InterWest Health Partners Board Member 000 0000
James Heath Ph.D Self Co-Founder & Board Member 000 0000
Junfeng Wang Legend Capital Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Indi Molecular Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Indi Molecular Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Legend Capital Venture Capital Minority 000 0000 000000 0
M Ventures Corporate Venture Capital Minority 000 0000 000000 0
Sabey Corporation Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »